3C Therapeutics Inc.
$140,000.00 CAD
≈ 22 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2026-2027
- Agreement period
- April 1, 2026 – March 31, 2027
- Reference
- nrc-cnrc:172-2026-2027-Q1-1042828
Published purpose
This project will develop, screen, and validate kinase-targeting degraders conjugated to non-antibody delivery moieties to inform antibody-directed optimization of Degrader-Antibody Conjugates, enabling rapid identification and prioritization of KRAS-targeting cancer therapeutic candidates for preclinical development.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported August 10, 2026 from open.canada.ca Grants & Contributions